Ocuphire Pharma Inc (NASDAQ: OCUP)’s stock price has plunge by -8.93relation to previous closing price of 1.68. Nevertheless, the company has seen a -10.79% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-06 that FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company’s lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, and the Retinal Imaging Biomarkers & Endpoints Summit meeting June 25-27 in Boston.
Is It Worth Investing in Ocuphire Pharma Inc (NASDAQ: OCUP) Right Now?
OCUP has 36-month beta value of 0.34. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OCUP is 23.41M, and currently, short sellers hold a 5.33% ratio of that float. The average trading volume of OCUP on June 20, 2024 was 187.14K shares.
OCUP’s Market Performance
OCUP’s stock has seen a -10.79% decrease for the week, with a -9.20% drop in the past month and a -19.90% fall in the past quarter. The volatility ratio for the week is 5.74%, and the volatility levels for the past 30 days are at 5.92% for Ocuphire Pharma Inc The simple moving average for the past 20 days is -10.32% for OCUP’s stock, with a -41.07% simple moving average for the past 200 days.
OCUP Trading at -11.35% from the 50-Day Moving Average
After a stumble in the market that brought OCUP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.59% of loss for the given period.
Volatility was left at 5.92%, however, over the last 30 days, the volatility rate increased by 5.74%, as shares sank -14.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.39% lower at present.
During the last 5 trading sessions, OCUP fell by -10.79%, which changed the moving average for the period of 200-days by -61.65% in comparison to the 20-day moving average, which settled at $1.6930. In addition, Ocuphire Pharma Inc saw -49.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUP starting from Jayagopal Ashwath, who purchase 3,500 shares at the price of $1.76 back on May 22 ’24. After this action, Jayagopal Ashwath now owns 78,500 shares of Ocuphire Pharma Inc, valued at $6,178 using the latest closing price.
Magrath George, the Chief Executive Officer of Ocuphire Pharma Inc, purchase 5,000 shares at $1.75 during a trade that took place back on May 17 ’24, which means that Magrath George is holding 430,000 shares at $8,772 based on the most recent closing price.
Stock Fundamentals for OCUP
Current profitability levels for the company are sitting at:
- -0.64 for the present operating margin
- 1.0 for the gross margin
The net margin for Ocuphire Pharma Inc stands at -0.59. The total capital return value is set at -0.26. Equity return is now at value -25.89, with -23.24 for asset returns.
Currently, EBITDA for the company is -10.56 million with net debt to EBITDA at 4.03. When we switch over and look at the enterprise to sales, we see a ratio of -0.39. The receivables turnover for the company is 6.1for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.96.
Conclusion
To put it simply, Ocuphire Pharma Inc (OCUP) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
